Evidence map›Paper›PMID 23030352›Full record

ReviewCurrent drug abuse reviews2012

Substance of abuse and movement disorders: complex interactions and comorbidities.

Andres Deik, Rachel Saunders-Pullman, Marta San Luciano

Abstract readReview
In one paragraph

Review in Current drug abuse reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 81 citations in OpenAlex.

  1. Attention bias modification in drug addiction: Enhancing control of subsequent habits.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Trial
  2. Movement disorders associated with diarrhoea.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  3. Frozen in Addiction: A New Wave of Drug-Induced Movement Disorders?Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Postanoxia-Induced Chorea Treated with Intravenous Fentanyl.Case reports in neurological medicine · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cocaine-induced Pisa syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Article
  16. Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andres DeikBeth Israel Medical Center, NY, USA.
Rachel Saunders-Pullman
Marta San Luciano
Mount Sinai Beth Israel · US

Funding

Phenotypic Spectrum of LRRK2 MutationsK02NS073836 · NINDS · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI SAUNDERS-PULLMAN, RACHEL · 2011 to 2015
$879k
Gender and Hormonal Differences in Parkinson's DiseaseK23NS047256 · NINDS · BETH ISRAEL MEDICAL CTR (NEW YORK) · PI SAUNDERS-PULLMAN, RACHEL · 2004 to 2008
$869k
NINDS NIH HHS K02 NS073836NINDS NIH HHS K23 NS047256
6 · The paper itself

Abstract

The relationship between movement disorders and substance abuse, which we previously reviewed, is updated. We examine these relationships bidirectionally with focus on drugs of abuse that are known to cause movement disorders, as well as primary movement disorders that are associated with use and abuse of alcohol and dopaminergic medications. First, we review the movement disorders that may develop from the acute use or withdrawal of frequent drugs of abuse, including alcohol, cocaine, heroin, amphetamine and methcathinone. We then comment on the interaction between alcoholism and alcohol-responsive movement disorders, such as essential tremor and myoclonus-dystonia. Lastly, we discuss the potential for abuse of antiparkinsonian dopaminergic agents in patients with Parkinson's disease (PD).

Indexed as

AlcoholismAnimalsAntiparkinson AgentsDopamineDopamine AgentsHumansMovement DisordersParkinson DiseaseSubstance-Related DisordersSubstance Withdrawal SyndromeAntiparkinson AgentsDopamineDopamine Agents

Identifiers

PMID23030352
PMCPMC3966544
OpenAlexW2146190598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.